These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 37111283)

  • 1. A Real-Life Study on the Use of Tildrakizumab in Psoriatic Patients.
    Campione E; Lambiase S; Gaeta Shumak R; Galluzzo M; Lanna C; Costanza G; Borselli C; Artosi F; Cosio T; Tofani L; Dattola A; Di Daniele F; Bianchi L
    Pharmaceuticals (Basel); 2023 Mar; 16(4):. PubMed ID: 37111283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
    Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
    J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 64-week phase 3 study (reSURFACE 1).
    Igarashi A; Nakagawa H; Morita A; Okubo Y; Sano S; Imafuku S; Tada Y; Honma M; Mendelsohn AM; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):853-863. PubMed ID: 33630387
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting.
    Burlando M; Castelli R; Cozzani E; Parodi A
    Drugs Context; 2021; 10():. PubMed ID: 34104197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brodalumab and ixekizumab, anti-interleukin-17-receptor antibodies for psoriasis: a critical appraisal.
    Spuls PI; Hooft L
    Br J Dermatol; 2012 Oct; 167(4):710-3; discussion 714-5. PubMed ID: 23013312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks.
    Reich K; Warren RB; Iversen L; Puig L; Pau-Charles I; Igarashi A; Ohtsuki M; Falqués M; Harmut M; Rozzo S; Lebwohl MG; Cantrell W; Blauvelt A; Thaçi D
    Br J Dermatol; 2020 Mar; 182(3):605-617. PubMed ID: 31218661
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tildrakizumab in Complex Psoriatic Patients: An Experience in Emilia-Romagna (Italy).
    Bardazzi F; Viviani F; Piraccini BM; Lasagni C; Bigi L; Manfredini M; Pongetti L; Di Lernia V; Corazza M; Pepe F
    J Cutan Med Surg; 2023; 27(2):126-132. PubMed ID: 36995351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tildrakizumab for the treatment of psoriasis.
    Sinclair R; Thirthar Palanivelu V
    Expert Rev Clin Immunol; 2019 Jan; 15(1):5-12. PubMed ID: 30394141
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness and Safety After a Switch to Tildrakizumab: A Real World Multicenter Italian Study in Psoriasis.
    Di Brizzi EV; Buononato D; Benvenuto P; Argenziano G; De Pasquale R; Fiorella CS; Giofrè C; Musumeci ML; Palazzo G; Zichichi L; Balato A
    Dermatol Pract Concept; 2023 Oct; 13(4):. PubMed ID: 37992389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study.
    Megna M; Tommasino N; Potestio L; Battista T; Ruggiero A; Noto M; Fabbrocini G; Genco L
    J Dermatolog Treat; 2022 Sep; 33(6):2813-2820. PubMed ID: 35603992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials.
    Reich K; Papp KA; Blauvelt A; Tyring SK; Sinclair R; Thaçi D; Nograles K; Mehta A; Cichanowitz N; Li Q; Liu K; La Rosa C; Green S; Kimball AB
    Lancet; 2017 Jul; 390(10091):276-288. PubMed ID: 28596043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.
    Frampton JE
    Am J Clin Dermatol; 2019 Apr; 20(2):295-306. PubMed ID: 30924030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: A 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis).
    Narcisi A; Valenti M; Gargiulo L; Ibba L; Amoruso F; Argenziano G; Bardazzi F; Burlando M; Carrera CG; Damiani G; Dapavo P; Dini V; Franchi C; Girolomoni G; Guarneri C; Loconsole F; Sampogna F; Travaglini M; Malagoli P; Costanzo A
    J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):93-103. PubMed ID: 36156312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis.
    Galluzzo M; Talamonti M; Cioni A; Maffei V; Shumak RG; Tofani L; Bianchi L; Campione E
    J Clin Med; 2022 May; 11(9):. PubMed ID: 35566756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective and Safe Treatment of Psoriatic Disease with the Anti-IL-23p19 Biologic Tildrakizumab: Results of a Real-World Prospective Cohort Study in Nonselected Patients.
    Drerup KA; Seemann C; Gerdes S; Mrowietz U
    Dermatology; 2022; 238(4):615-619. PubMed ID: 34775387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1).
    Imafuku S; Nakagawa H; Igarashi A; Morita A; Okubo Y; Sano S; Tada Y; Nemoto O; Rozzo SJ; Kawamura M; Ohtsuki M
    J Dermatol; 2021 Jun; 48(6):844-852. PubMed ID: 33523513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
    Berenguer-Ruiz S; Aparicio-Domínguez M; Herranz-Pinto P; Ruíz-Villaverde R; López-Ferrer A; Santos-Juanes J; Rodríguez Fernández-Freire L; Hospital-Gil M; Arias-Santiago S; Carretero-Hernández G; Mateu-Puchades A; Ferran M; Del Alcázar E; Santos-Alarcón S; Garcia-Latasa de Aranibar FJ; Belinchón-Romero I; González-Cantero Á; Ruíz-Genao D; Eiris-Salvado N; Rocamora-Durán V; Rivera-Diaz R; de la Cueva P; Daudén E; Salgado-Boquete L; Llamas-Velasco M;
    J Eur Acad Dermatol Venereol; 2023 Dec; 37(12):2517-2525. PubMed ID: 37625815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate-to-severe chronic plaque psoriasis.
    Poulin Y; Ramon M; Rosoph L; Weisman J; Mendelsohn AM; Parno J; Rozzo SJ; Lee P
    J Eur Acad Dermatol Venereol; 2020 Jul; 34(7):1500-1509. PubMed ID: 31919889
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of tildrakizumab on quality of life in patients suffering from moderate-to-severe psoriasis: a 36-week prospective, monocentric, real-life, observational study.
    Cacciapuoti S; Battista T; Potestio L; Scalvenzi M; Megna M; Ruggiero A
    Clin Exp Dermatol; 2024 Oct; ():. PubMed ID: 39400048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Short-term efficacy of tildrakizumab on difficult-to-treat areas: a real-world experience.
    Cacciapuoti S; Potestio L; Gallo L; Musumeci ML; Caldarola G; D'Amico D; Caudullo F; Papaianni V; De Simone C; Peris K; Megna M
    Int J Dermatol; 2024 Jul; ():. PubMed ID: 38997809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.